HOME >> BIOLOGY >> NEWS
A friendly foe -- Bacteria residing in the gut boost immune response to tumors

One potent, immune-based treatment for cancer is total body irradiation (TBI). This approach first depletes the body of the population of immune cells known as lymphocytes and then involves the adoptive transfer of tumor-specific T cells to the patient. Lymphodepletion has previously been shown to improve the ability of tumor-specific T cells to cause tumor regression. In a study appearing online on July 26 in advance of publication in the August print issue of the Journal of Clinical Investigation, Nicholas Restifo and colleagues from the National Cancer Institute show that, in mice, lymphodepletion does not fully account for the tumor regression observed following TBI. They show that a disruption of the population of bacteria that normally reside in the gut without causing disease also plays a role in the effectiveness of this therapeutic approach for cancer.

A specific population of bacteria present in our gut is crucial to our health. However, some treatments for cancer, particularly those that deplete the bodys immune cells, have high potential to disrupt the natural balance between our bodies and these commensal microorganisms, causing disease. Restifo and colleagues subjected mice genetically deficient in lymphocytes to TBI and found that, like TBI-treated mice with intact lymphocytes, TBI was still able to positively augment the function of adoptively transferred tumor-specific CD8+ T cells and cause tumor regression. This surprising result indicated that another mechanism for the efficacy of TBI also exists. They found that in these mutant, irradiated mice the lining of their gut was injured, allowing the passage of commensal bacteria from the gut to the lymph nodes, where the immune response to their presence increased the activation of tumor-specific CD8+ T cells and resulted in tumor regression. This effect was found to involve toll-like receptor 4. Conversely, a reduction in the number of host microorganisms by the use of antibiotics reduce
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
26-Jul-2007


Page: 1 2

Related biology news :

1. FSU pushing boundaries with environmentally friendly community
2. New Queens study offers environmentally friendly solution to oil industry needs
3. Eco-friendly bug sucker
4. Research shows Europeans prefer environmentally-friendly seafood
5. Switchable solvents make chemical manufacturing more environmentally-friendly
6. Chemical Society announces EPA awards for environmentally friendly technologies
7. Plant pathologists evaluate eco-friendly alternatives to methyl bromide
8. Fungus-friendly scientists meet in Tucson
9. Bacteria may not hasten death
10. Bacteria ferry nanoparticles into cells for early diagnosis, treatment
11. Bacteria show promise in fending off global amphibian killer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2019)... ... ... Mount Sinai researchers have discovered how the enzyme DNA polymerase delta works to ... a study published in Nature Structural & Molecular Biology, the team also reported how ... diseases. , “DNA polymerase delta serves as the duplicating machine for the millions to ...
(Date:9/30/2019)... ... September 30, 2019 , ... USDM Life Sciences ... life science organizations to accelerate innovation and maximize productivity, announces that David Blewitt ... What: Just 30 days to 21 CFR Part 11 compliance with Box, When: ...
(Date:9/25/2019)... ... September 25, 2019 , ... Modality Solutions, a ... on Inc. Magazine’s annual Inc. 5000 list, the most prestigious ranking of the ... Based on this growth, the Houston-based firm also ranked No. 47 in its ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... BOSTON (PRWEB) , ... October 03, 2019 , ... Yesterday, ... 2-3, Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., discussed important ... To an attendee audience including both developers and suppliers of clinical trials, in ...
(Date:9/24/2019)... ... 2019 , ... Personalized Stem Cells, Inc (“PSC”), ... clinical trial sites and physician investigators. The clinical trial sites are now ... Clinical trial sites are currently located in San Diego and Los Angeles California, ...
(Date:9/17/2019)... ... September 17, 2019 , ... Tucker, a Labrador retriever, was ... months old, Tucker was limping and lame on his right hip and elbow. At ... it was called “the worst case the vet had seen.” He was prescribed pain ...
(Date:9/17/2019)... ... September 16, 2019 , ... MyBioGate Global Healthcare Innovation ... Biotech Week Boston, a forum organized by MyBioGate, Inc. and CUBIO Innovation Center ... a careful process of evaluation, twelve companies out of over 200 applications were ...
Breaking Biology Technology:
Cached News: